Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
BMS to pay $515M in kickback case
Bristol-Myers Squibb now has the dubious distinction of the third-largest court settlement between a drug maker and the U.S. Attorney's office in Massachusetts. The drug maker agreed to pay $515 million to settle kickback claims.
It's not the money that's most worrisome, though, but the behind-the-curtain machinations of a special Bristol-Myers sales force charged with marketing the antipsychotic Abilify for off-label uses--included one use that the FDA had warned against. The company also defrauded Medicaid with a pricing scheme on the antidepressant Serzone, and inflated prices of various cancer drugs and generics.
- see the U.S. Attorney's statement on the settlement
- read Bristol-Myers' statement
- read the report from the Boston Globe
Related Articles:
Better times ahead for BMS? Report
Probation draws to a close for Bristol-Myers. Report
FBI agents raid BMS office in deal probe. Report
Comments (1) | Post a comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
